Epilepsy is one of the most common neurological disorders, affecting around 50 million people worldwide [1].  Despite the versatile variety of anti-epileptic drugs, about 20-30% of patients resist conservative treatment [2]. Brain surgery has been considered the most effective option for the patients with pharmacoresistant epilepsy. The effectiveness of surgery in patients with pharmacoresistant epilepsy vary markedly (from 30 to 90%), according to the literature, that diversity can be explained by the differences in population and surgical option, but not least effectiveness of surgery depends on the accurate localization of the epileptogenic lesion [3].

   Standard diagnostic algorithm for the patients with epilepsy includes scalp Video-EEG monitoring and MRI. In 20-50% of patients these methods fail to localize epileptogenic zone, or the results of MRI and EEG are discordant [4,5]. Even though  stereo EEG (SEEG) has been considered the gold standard for spatiotemporal definition of seizure-onset zone, specific MRI techniques and radionuclide methods can provide additional information prior to the invasive procedure.  PET/MRI is a new hybrid diagnostic method that simultaneously collect metabolic and molecular information from PET and anatomical information from MRI and perform combined functional and structural analysis.

   The purpose of our study was to evaluate the possibilities of interictal 18F-FDG PET/MRI of the brain in patients with pharmacoresistant epilepsy.